AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus
Chronic Kidney Diseases

Interventions: Drug: Cotadutide 100 micrograms
Drug: Cotadutide 300 micrograms
Drug: Cotadutide 600 micrograms
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2020-08-17

Last Posted Date: 2025-01-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 248

Registration Number: NCT04515849

Locations: 🇬🇧
Research Site, London, United Kingdom

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

Phase 1

Completed

Conditions: COVID-19

Interventions: Combination Product: AZD7442
Other: Placebo

First Posted Date: 2020-08-11

Last Posted Date: 2024-10-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 60

Registration Number: NCT04507256

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Phase 1

Completed

Conditions: Clear Cell Renal Cell Cancer
Non-Small-Cell Lung Cancer
Triple Negative Breast Neoplasms
Gastroesophageal Cancer
Cervical Cancer
Squamous Cell Cancer of Head and Neck
Small Cell Lung Cancer
Melanoma
Advanced Solid Tumours

Interventions: Drug: AZD8701
Biological: Durvalumab

First Posted Date: 2020-08-07

Last Posted Date: 2024-11-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 60

Registration Number: NCT04504669

Locations: 🇪🇸
Research Site, Madrid, Spain

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Phase 3

Active, not recruiting

Conditions: Advanced or Metastatic Breast Cancer

Interventions: Drug: Capecitabine
Drug: Trastuzumab deruxtecan
Drug: Paclitaxel
Drug: Nab-Paclitaxel

First Posted Date: 2020-07-31

Last Posted Date: 2025-04-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 866

Registration Number: NCT04494425

Locations: 🇬🇧
Research Site, Northwood, United Kingdom

Selumetinib Paediatric NF1 Japan Study

Phase 1

Completed

Conditions: Neurofibromatosis Type 1

Interventions: Drug: Selumetinib

First Posted Date: 2020-07-31

Last Posted Date: 2023-04-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 12

Registration Number: NCT04495127

Locations: 🇯🇵
Research Site, Setagaya-ku, Japan

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Phase 2

Completed

Conditions: Progressive Metastatic Castrate-Resistant Prostate Cancer

Interventions: Drug: AZD4635
Drug: Durvalumab
Drug: Cabazitaxel

First Posted Date: 2020-07-31

Last Posted Date: 2023-08-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT04495179

Locations: 🇪🇸
Research Site, Madrid, Spain

A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects

Phase 1

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: Midazolam
Drug: AZD5718

First Posted Date: 2020-07-30

Last Posted Date: 2020-11-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT04492709

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Phase 3

Active, not recruiting

Conditions: Hormone-Sensitive Prostate Cancer

Interventions: Other: Placebo
Drug: Capivasertib
Drug: Abiraterone Acetate

First Posted Date: 2020-07-30

Last Posted Date: 2025-04-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 1012

Registration Number: NCT04493853

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Phase 2

Terminated

Conditions: Chronic Kidney Disease

Interventions: Drug: AZD5718
Drug: Dapagliflozin 10 mg
Drug: Placebo

First Posted Date: 2020-07-30

Last Posted Date: 2024-12-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 613

Registration Number: NCT04492722

Locations: 🇺🇦
Research Site, Zhytomyr, Ukraine

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Phase 1

Completed

Conditions: Infectious Disease

Interventions: Drug: Acalabrutinib
Drug: Rabeprazole

First Posted Date: 2020-07-28

Last Posted Date: 2020-10-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 35

Registration Number: NCT04489797

Locations: 🇺🇸
Research Site, Anaheim, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy